US OptionsDetailed Quotes
AUTL250516P2000
- 0.00
- 0.000.00%
15min DelayClose Apr 25 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover0.00%IV-50.38%PremiumMay 16, 2025Expiry Date0.67Intrinsic Value100Multiplier18DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.86Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Autolus Therapeutics Stock Discussion
First regulatory approval validates Autolus' technology platform and establishes commercial pathway, though NICE approval remains critical next step.
This MHRA conditional authorization represents a transformative milestone for Autolus Therapeutics, validating both their lead product and underlying technology platform. As the company's first regulatory approval, it establishes Autolus as an emerging commercial-stage biopharmaceutic...
MHRA approval of AUCATZYL for r/r B-ALL represents significant treatment advance with impressive 76.6% response rate and manageable safety profile.
The MHRA's conditional authorization of AUCATZYL marks a critical advancement for adult patients with r/r B-ALL, a disease with historically poor outcomes. The FELIX study results are compelling, showing a 76.6% complete response rate in the pivotal cohort, with 21.2 months median response dur...
Revolutionary Leukemia Treatment: Autolus's CAR-T Therapy Secures First-Ever UK Approval with 77% Success Rate
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Autolus Therapeutics (NASDAQ: AUTL)presented clinical data updates at ASH 2024, featuring one oral and three poster presentations about obecabtagene autoleucel (obe-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
The FELIX trial demonstrated that obe-cel treatment achieved deep molecular remission in 84% of responde...
4 MINUTES AGO, 7:30 PM EST
VIA GLOBENEWSWIRE
ya I'm getting in here
No comment yet